Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totaling 117,132 shares, a growth of 90.7% from the August 15th total of 61,410 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 34,578 shares, the short-interest ratio is presently 3.4 days.

Estrella Immunopharma Stock Performance

Shares of NASDAQ ESLA traded down $0.02 during trading on Tuesday, hitting $0.61. The company had a trading volume of 48,131 shares, compared to its average volume of 100,725. Estrella Immunopharma has a 52 week low of $0.58 and a 52 week high of $3.15. The business’s 50-day moving average is $0.74 and its 200 day moving average is $1.06. The company has a market cap of $26.58 million, a P/E ratio of -2.55 and a beta of 0.88.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.04. On average, research analysts expect that Estrella Immunopharma will post -0.25 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.00.

Hedge Funds Weigh In On Estrella Immunopharma

An institutional investor recently bought a new position in Estrella Immunopharma stock. BlackRock Inc. acquired a new position in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned 0.12% of Estrella Immunopharma at the end of the most recent quarter. 0.35% of the stock is owned by institutional investors.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.